X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (984) 984
Book Review (135) 135
Conference Proceeding (25) 25
Publication (21) 21
Dissertation (7) 7
Paper (3) 3
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
olmesartan medoxomil (697) 697
index medicus (604) 604
humans (450) 450
hypertension (375) 375
male (359) 359
hypertension - drug therapy (325) 325
olmesartan (289) 289
tetrazoles - therapeutic use (263) 263
imidazoles - therapeutic use (258) 258
female (250) 250
pharmacology & pharmacy (247) 247
blood pressure - drug effects (236) 236
antihypertensive agents - therapeutic use (218) 218
middle aged (198) 198
animals (193) 193
peripheral vascular disease (186) 186
tetrazoles - pharmacology (161) 161
drug therapy, combination (159) 159
imidazoles - pharmacology (159) 159
aged (156) 156
hydrochlorothiazide (148) 148
treatment outcome (148) 148
angiotensin ii type 1 receptor blockers - therapeutic use (142) 142
tetrazoles - administration & dosage (142) 142
amlodipine (137) 137
imidazoles - administration & dosage (136) 136
tetrazoles - adverse effects (136) 136
imidazoles - adverse effects (133) 133
antihypertensive agents - administration & dosage (131) 131
hypertension - physiopathology (130) 130
antihypertensive agents - adverse effects (127) 127
adult (126) 126
rats (123) 123
blood pressure (111) 111
double-blind (107) 107
blood-pressure (105) 105
double-blind method (98) 98
medicine & public health (92) 92
dose-response relationship, drug (90) 90
angiotensin (86) 86
drug therapy (82) 82
angiotensin ii type 1 receptor blockers - pharmacology (81) 81
antihypertensive agents - pharmacology (81) 81
drug combinations (78) 78
valsartan (75) 75
internal medicine (74) 74
pharmacology/toxicology (73) 73
amlodipine besylate (71) 71
efficacy (71) 71
angiotensin receptor antagonists (70) 70
cardiac & cardiovascular systems (69) 69
combination therapy (69) 69
angiotensin ii type 1 receptor blockers - administration & dosage (68) 68
angiotensin ii type 1 receptor blockers - adverse effects (68) 68
pharmacotherapy (68) 68
time factors (62) 62
amlodipine - therapeutic use (61) 61
medoxomil (61) 61
pharmacokinetics (61) 61
research (60) 60
management (59) 59
prospective studies (59) 59
amlodipine - administration & dosage (58) 58
losartan (57) 57
hydrochlorothiazide - therapeutic use (56) 56
dosage and administration (55) 55
hydrochlorothiazide - administration & dosage (55) 55
tetrazoles - pharmacokinetics (55) 55
imidazoles - pharmacokinetics (54) 54
combination (52) 52
calcium channel blockers - therapeutic use (48) 48
safety (48) 48
oxidative stress (47) 47
angiotensin ii (45) 45
cardiology (45) 45
amlodipine - adverse effects (44) 44
tablets (44) 44
aged, 80 and over (43) 43
analysis (43) 43
antihypertensive agents - pharmacokinetics (43) 43
antihypertensive drugs (43) 43
blood pressure monitoring, ambulatory (43) 43
chemistry, analytical (43) 43
hypertension - complications (43) 43
risk factors (43) 43
benzimidazoles - therapeutic use (40) 40
blood pressure - physiology (40) 40
disease models, animal (40) 40
diuretics (39) 39
hydrochlorothiazide - adverse effects (39) 39
mortality (38) 38
renin-angiotensin system - drug effects (38) 38
randomized controlled trials as topic (37) 37
rats, sprague-dawley (37) 37
drugs (36) 36
medicine, general & internal (36) 36
mice (36) 36
therapy (36) 36
administration, oral (35) 35
angiotensin-converting enzyme inhibitors - therapeutic use (35) 35
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (926) 926
German (14) 14
Spanish (14) 14
Russian (12) 12
French (9) 9
Chinese (6) 6
Japanese (6) 6
Portuguese (3) 3
Korean (2) 2
Croatian (1) 1
Dutch (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Clinical Hypertension, ISSN 1524-6175, 09/2017, Volume 19, Issue 9, pp. 874 - 883
This 52‐week, randomized, open‐label study evaluated long‐term safety/tolerability of fixed‐dose combination azilsartan medoxomil/chlorthalidone ( AZL ‐M/ CLD... 
chlorthalidone | fixed‐dose combination | angiotensin receptor blocker | diuretic | azilsartan | fixed-dose combination | MANAGEMENT | REDUCING CARDIOVASCULAR EVENTS | RECEPTOR BLOCKERS | MEDOXOMIL | BLOOD-PRESSURE | HYDROCHLOROTHIAZIDE | SERUM CREATININE | THERAPY | PERIPHERAL VASCULAR DISEASE | HYPERTENSION | Oxadiazoles - administration & dosage | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Essential Hypertension - drug therapy | Drug Therapy, Combination - adverse effects | Benzimidazoles - administration & dosage | Olmesartan Medoxomil - therapeutic use | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Chlorthalidone - therapeutic use | Essential Hypertension - classification | Olmesartan Medoxomil - administration & dosage | Olmesartan Medoxomil - adverse effects | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - therapeutic use | Oxadiazoles - therapeutic use | Oxadiazoles - adverse effects | Chlorthalidone - administration & dosage | Diuretics - therapeutic use | Aged | Hydrochlorothiazide - therapeutic use | Hypertension | Dosage and administration | Chlorthalidone | Drug therapy, Combination | Comparative analysis | Index Medicus
Journal Article
Journal Article
Regulatory Toxicology and Pharmacology, ISSN 0273-2300, 12/2016, Volume 82, pp. 20 - 31
Poor aqueous solubility and unfavourable de-esterification of olmesartan medoxomil (a selective angiotensin II receptor blocker), results in low oral... 
Olmesartan nanoemulsion | Brain penetration | Tissue distribution | Sub-chronic toxicity | Hematological parameters | Histopathological characteristics | MEDICINE, LEGAL | RATS | FORMULATION | HYPERTENSIVE PATIENTS | BIOAVAILABILITY | STROKE | PHARMACOKINETICS | DISEASE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | ABSORPTION | ORGAN WEIGHT | BRAIN | Emulsions | Olmesartan Medoxomil - pharmacokinetics | Rats, Wistar | Antihypertensive Agents - administration & dosage | Body Weight - drug effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Olmesartan Medoxomil - chemistry | Drug Carriers | Brain - metabolism | Nanoparticles | Tissue Distribution | Tandem Mass Spectrometry | Antihypertensive Agents - toxicity | Olmesartan Medoxomil - toxicity | Water - chemistry | Chromatography, Liquid | Drug Compounding | Oils - chemistry | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Olmesartan Medoxomil - administration & dosage | Reproducibility of Results | Angiotensin II Type 1 Receptor Blockers - chemistry | Risk Assessment | Administration, Oral | Toxicity Tests, Subchronic | Antihypertensive Agents - pharmacokinetics | Biomarkers - blood | Permeability | Antihypertensive Agents - chemistry | Eating - drug effects | Organ Size - drug effects | Animals | Nanomedicine - methods | Drinking - drug effects | Angiotensin II Type 1 Receptor Blockers - toxicity | Stroke (Disease) | Medical colleges | Safety and security measures | Air bases | Pharmacy | Angiotensin | Drugstores | Comparative analysis | Index Medicus
Journal Article
Colloids and Surfaces B: Biointerfaces, ISSN 0927-7765, 03/2014, Volume 115, pp. 286 - 294
Journal Article
Clinical Drug Investigation, ISSN 1173-2563, 2009, Volume 29, Issue 1, pp. 11 - 25
Journal Article
Journal Article
Toxicology and Applied Pharmacology, ISSN 0041-008X, 08/2013, Volume 271, Issue 1, pp. 106 - 113
Journal Article
Crystal Research and Technology, ISSN 0232-1300, 04/2017, Volume 52, Issue 4, pp. 1700038 - n/a
The polymorphic transformation of amorphous form to Form I of olmesartan medoxomil, an angiotensin II receptor blocker, was studied in methanol‐water mixture... 
SMPT | olmesartan medoxomil | amorphous | kinetics | polymorph | POLYMERS | III PIRACETAM | DOSAGE FORMS | ETHANOL | STATE | CRYSTALLOGRAPHY | NUCLEATION | Solvents | Receptors | Additives | Nucleation | Moisture content | Crystals | Transformations | Monitoring
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 08/2018, Volume 26, Issue 14, pp. 4348 - 4359
We have elaborated a one-pot three-component assembly of trityl olmesartan medoxomil starting from commercially available ethyl... 
Drugs | Heterocycles | Multicomponent reactions | SN2 reaction | Olmesartan | Alkylation | Ester hydrolysis<